Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,025,314
  • Shares Outstanding, K 94,689
  • Annual Sales, $ 0 K
  • Annual Income, $ -100,160 K
  • EBIT $ -147 M
  • EBITDA $ -155 M
  • 60-Month Beta 0.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.04

Options Overview Details

View History
  • Implied Volatility 108.05% ( +3.56%)
  • Historical Volatility 44.54%
  • IV Percentile 67%
  • IV Rank 42.98%
  • IV High 246.55% on 09/16/24
  • IV Low 3.66% on 12/14/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 351
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 10,493
  • Open Int (30-Day) 18,473

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.39
  • Number of Estimates 5
  • High Estimate -0.37
  • Low Estimate -0.44
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +17.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.82 +9.29%
on 11/18/24
38.12 -14.51%
on 11/11/24
-2.26 (-6.48%)
since 10/21/24
3-Month
16.60 +96.33%
on 09/16/24
38.12 -14.51%
on 11/11/24
+11.65 (+55.64%)
since 08/21/24
52-Week
5.93 +449.58%
on 12/01/23
38.12 -14.51%
on 11/11/24
+26.25 (+414.04%)
since 11/21/23

Most Recent Stories

More News
MarketBeat Week in Review – 9/23 - 9/27

Stocks had a mostly bullish week as stimulus efforts in the U.S. and China enhanced risk-on sentiment, but next week's jobs report could spark a larger rally

MSFT : 412.88 (-0.43%)
NVDA : 146.64 (+0.51%)
CEG : 250.38 (+6.35%)
EBAY : 61.86 (+1.71%)
AZO : 3,061.90 (+0.40%)
EWTX : 32.17 (+0.69%)
CAT : 390.10 (+2.25%)
AMD : 137.06 (-0.39%)
RIVN : 10.24 (+1.89%)
RKLB : 22.17 (+9.86%)
FDX : 294.81 (+2.35%)
PLTR : 61.40 (-1.16%)
Analysts Think There's Still Time to Get in on Edgewise, Up 332%

Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?

CYTK : 48.09 (-3.55%)
EWTX : 32.17 (+0.69%)
BMY : 58.36 (+0.83%)
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Edgewise Therapeutics is rocketing higher on positive results for its HCM combating treatment and short-covering. Expect volatility in the weeks ahead.

EWTX : 32.17 (+0.69%)
Why Edgewise Therapeutics Stock Is Up 50% on Thursday

One of the biopharma company's heart drugs performs as well as initially hoped.

EWTX : 32.17 (+0.69%)
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street

Analysts have high hopes for these three innovation companies in 2024.

BEAM : 24.00 (-2.00%)
EWTX : 32.17 (+0.69%)
GLUE : 8.80 (+5.26%)
Edgewise Therapeutics to Present at Upcoming Investor Conferences

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 32.17 (+0.69%)
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 32.17 (+0.69%)
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 32.17 (+0.69%)
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 32.17 (+0.69%)
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle...

EWTX : 32.17 (+0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

See More

Key Turning Points

3rd Resistance Point 33.35
2nd Resistance Point 32.71
1st Resistance Point 32.33
Last Price 32.17
1st Support Level 31.32
2nd Support Level 30.68
3rd Support Level 30.30

See More

52-Week High 38.12
Last Price 32.17
Fibonacci 61.8% 25.82
Fibonacci 50% 22.02
Fibonacci 38.2% 18.23
52-Week Low 5.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar